NovaMedica

NovaMedica operates as a specialized commercialization and local production partner for international pharmaceutical innovations in Russia. The company's strategy centers on identifying and transferring advanced medical technologies, navigating the local regulatory landscape, and ensuring local GMP manufacturing to bring products to the Russian healthcare system. Its current portfolio consists of several commercial-stage products for conditions such as dementia, migraine, pain, schizophrenia, and insomnia, indicating it is a revenue-generating entity. As a private company, it plays a role in bridging global pharmaceutical R&D with the specific needs and regulations of the Russian market.

Integrated regulatory, local GMP manufacturing, and commercialization platform for in-licensing and localizing innovative small molecule drugs in the Russian market.

NovaMedica competes with multinational pharmaceutical companies that have their own Russian subsidiaries, as well as large local generic manufacturers. Its niche is as a specialized local partner for companies without a direct presence, competing on regulatory expertise, local manufacturing agility, and commercial focus.